share_log

Mizuho Upgrades Arcutis Biotherapeutics to Buy, Raises Price Target to $8

Benzinga ·  Jan 2 16:19

Mizuho analyst Uy Ear upgrades Arcutis Biotherapeutics (NASDAQ:ARQT) from Neutral to Buy and raises the price target from $4 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment